Value proposition

Developing mRNA vaccines and therapeutics

In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases.

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Read more about this acquisition: https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-14-15-26-25-2296830

Learn more about Sanofi: www.sanofi.com


Biotechnology, Rare Diseases, Vaccines, messenger RNA, mRNA, mRNA therapeutics, Pulmonary Diseases, Cystic Fibrosis, and Infectious Diseases